Physician profile
Anna M Pare
NPI 1437135274
$57,816.61
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $475 · 2021: $8,222 · 2022: $11K · 2023: $3,054 · 2024: $4,676 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $8,104 · Consulting Fee: $2,400 · Education: $86.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,533.49 |
| Food and Beverage | $8,103.82 |
| Consulting Fee | $2,400.00 |
| Education | $86.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $26,381.06 | 2019-2025 | Dysport, Aklief, Nemluvio |
| Allergan, INC. | $11,556.14 | 2019-2023 | |
| Aclaris Therapeutics, INC. | $5,619.65 | 2019 | |
| Abbvie INC. | $3,675.79 | 2020-2025 | |
| Merz North America, INC. | $2,688.49 | 2019-2023 | |
| Genzyme Corporation | $1,965.76 | 2021-2025 | |
| Revance Therapeutics, INC. | $1,291.74 | 2024-2025 | Daxxify, Daxi |
| Incyte Corporation | $780.01 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $708.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $586.66 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $431.89 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $349.87 | 2020-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $248.21 | 2021-2024 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $243.58 | 2021-2025 | Bimzelx |
| Pfizer INC. | $236.18 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $202.96 | 2019-2025 | Adbry |
| Janssen Biotech, INC. | $169.96 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Mayne Pharma Commercial LLC | $116.90 | 2023-2025 | |
| Dermavant Sciences, INC. | $111.02 | 2023-2024 | Vtama |
| Organogenesis INC. | $64.45 | 2024-2025 | Via Matrix |
| Amgen INC. | $63.58 | 2021-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.17 | 2021-2024 | Jublia |
| Biofrontera INC. | $42.61 | 2021 | |
| Botanix Sb INC | $39.76 | 2025 | Sofdra |
| Almirall LLC | $33.03 | 2022-2025 | Seysara |
| Organon LLC | $31.78 | 2023-2024 | Hadlima, Renflexis |
| Sanofi-Aventis U.S. LLC | $23.89 | 2021 | |
| Epi Health, LLC | $19.39 | 2022 | |
| Lnhc, INC | $18.42 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2025 | Spevigo |
| Kerecis Limited | $15.77 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Emd Serono, INC. | $15.13 | 2022 | |
| Medtronic, INC. | $13.06 | 2023 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Pare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.